Sungwon Lim, Ph.D.
Pets with cancer deserve medical care as good as humans. We are seeing positive clinical outcomes with AI-driven functional personalized medicine services for canine lymphoma and leukemia patients.
Sungwon Lim is the CEO and Co-Founder of ImpriMed, Inc., a veterinary precision medicine startup that uses artificial intelligence on live cancer cell analytics to predict how a specific patient will respond to cancer therapy drugs before taking them. As a result of his background in research and development of novel cancer therapeutics, Dr. Lim knows how much time and effort it takes to develop new anticancer drugs — he is passionate about helping cancer patients who need effective treatment immediately.
ImpriMed’s goal is to match specific patients with drug treatment options that are currently available on the market and to find the best drug for each patient’s cancer. To achieve this, Dr. Lim is a strong advocate of functional precision medicine: personalizing a cancer treatment regimen based on functional responses of a patient’s ‘live’ cancer cells against various anticancer drugs.
Dr. Lim is a bioengineer and entrepreneur with 20 years of collective experiences in academia and biotech companies. He received his Ph.D. degree in Bioengineering from Stanford University and a Master’s degree in Translational Medicine from the UC Berkeley–UCSF Joint Bioengineering Program.
ImpriMed has built their AI-driven prediction models based on the database consisting of 2,500+ canine lymphoma patients. Their technology has been published in peer-reviewed scientific journal papers, including Veterinary and Comparative Oncology in October 2020 and more recently Veterinary Sciences in December 2021.
ImpriMed’s goal is to match specific patients with drug treatment options that are currently available on the market and to find the best drug for each patient’s cancer. To achieve this, Dr. Lim is a strong advocate of functional precision medicine: personalizing a cancer treatment regimen based on functional responses of a patient’s ‘live’ cancer cells against various anticancer drugs.
Dr. Lim is a bioengineer and entrepreneur with 20 years of collective experiences in academia and biotech companies. He received his Ph.D. degree in Bioengineering from Stanford University and a Master’s degree in Translational Medicine from the UC Berkeley–UCSF Joint Bioengineering Program.
ImpriMed has built their AI-driven prediction models based on the database consisting of 2,500+ canine lymphoma patients. Their technology has been published in peer-reviewed scientific journal papers, including Veterinary and Comparative Oncology in October 2020 and more recently Veterinary Sciences in December 2021.
